1. Home
  2. PYPD vs NKGN Comparison

PYPD vs NKGN Comparison

Compare PYPD & NKGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PYPD
  • NKGN
  • Stock Information
  • Founded
  • PYPD 2008
  • NKGN 2017
  • Country
  • PYPD Israel
  • NKGN United States
  • Employees
  • PYPD N/A
  • NKGN N/A
  • Industry
  • PYPD Medical/Dental Instruments
  • NKGN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PYPD Health Care
  • NKGN Health Care
  • Exchange
  • PYPD Nasdaq
  • NKGN Nasdaq
  • Market Cap
  • PYPD 16.3M
  • NKGN 14.1M
  • IPO Year
  • PYPD 2020
  • NKGN N/A
  • Fundamental
  • Price
  • PYPD $3.47
  • NKGN $0.28
  • Analyst Decision
  • PYPD Buy
  • NKGN
  • Analyst Count
  • PYPD 2
  • NKGN 0
  • Target Price
  • PYPD $12.00
  • NKGN N/A
  • AVG Volume (30 Days)
  • PYPD 4.6K
  • NKGN 360.2K
  • Earning Date
  • PYPD 11-06-2024
  • NKGN 11-12-2024
  • Dividend Yield
  • PYPD N/A
  • NKGN N/A
  • EPS Growth
  • PYPD N/A
  • NKGN N/A
  • EPS
  • PYPD N/A
  • NKGN N/A
  • Revenue
  • PYPD N/A
  • NKGN N/A
  • Revenue This Year
  • PYPD N/A
  • NKGN N/A
  • Revenue Next Year
  • PYPD N/A
  • NKGN N/A
  • P/E Ratio
  • PYPD N/A
  • NKGN N/A
  • Revenue Growth
  • PYPD N/A
  • NKGN N/A
  • 52 Week Low
  • PYPD $2.95
  • NKGN $0.27
  • 52 Week High
  • PYPD $9.20
  • NKGN $5.10
  • Technical
  • Relative Strength Index (RSI)
  • PYPD 46.98
  • NKGN 23.41
  • Support Level
  • PYPD $3.37
  • NKGN $0.36
  • Resistance Level
  • PYPD $3.65
  • NKGN $0.44
  • Average True Range (ATR)
  • PYPD 0.17
  • NKGN 0.04
  • MACD
  • PYPD -0.00
  • NKGN 0.00
  • Stochastic Oscillator
  • PYPD 36.36
  • NKGN 5.04

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

About NKGN NKGen Biotech Inc.

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

Share on Social Networks: